GenAu
Genetic Analysis Austria

Contact us! Matthias Wielscher, CEO
+43 (0)650 8641043
matthias.wielscher@meduniwien.ac.at

INNOVATION

- **One in depth analysis to answer all genetic questions throughout your lifetime.**
- **Patients have to consent to every new analysis.**
- **Your genome can get re-analysed as research evolves, because it stays the same throughout your life.**

KEY FACTS

Stage: Validated Prototype, applied for AWS and FFG funding.
Current need: VC/Business Angel to counterfincance FFG funding.
Use of funds: Further product development, IVDR certification.

TEAM

Dr. Matthias Wielscher,CEO
Geneticist at Medical University of Vienna with 15 years of experience in the field of diagnostics and Genetics

Moritz Stadler, CTO
5th year Medical Student of Medical University of Vienna, over 5 years of experience in Software development.

Dr. Moritz Imendörffler, CQO
Biotech engineer, over 10 years of experience in Software development and validation.

BUSINESS MODEL

Software as a service for
Genetics labs
Large scale biobanks
Whole Genome Sequencing for
Hospitals (public and private)
Expert physicians
Insurance companies

PROBLEM

Our knowledge of the human genome is growing exponentially, yet medical professionals struggle to incorporate it into their decision making. Important research findings are neglected for a lack of simple, reliable and fast genetic analysis. We are a pioneering genetic analysis company that aims to unlock the true potential of Next Generation Sequencing (NGS), bridging the gap between genetic research and healthcare with a standardized analysis workflow and data management system to ensure that valuable insights from genetic research can be effectively applied in patient care.

SOLUTION



Whole Genome Sequencing (WGS) allows us to read all of the 3.200.000.000 base pairs in your genome. Using Pharmacogenomics we identify gene variations affecting drug reactions and preventing adverse reactions to certain drugs based on an individual patient's genome. Severe disease screening detects mutations in key genes linked to major health risks that can be treated early on. Carrier screening assesses you and your partner's genes, determining your children's risk of genetic diseases like cystic fibrosis. Expert queries address physician-specific genetic inquiries over your lifetime, including rare diseases. Disease risk estimates use genetic data from over 100.000 people to calculate your personal risk for complex diseases such as Diabetes or heart attack allowing better clinical decision making. Currently when a patient's genome is sequenced, the generated data is only used once, despite the genome staying the same the entire life. We will create a way to continuously use a person's existing genetic data in day-to-day clinical applications.

MARKET

The global genomic revolution is underway, with the cost of sequencing dropping from 3 billion USD (first genome sequenced, 2003) to less than 300 USD (Q1, 2024). The market for whole genome sequencing is expected to grow from 750M USD (2017) to 3.8B USD (2027).

TRACTION

GENAU emerged as the winner of the 2023 digital iLAB contest. Our software is currently undergoing beta testing in collaboration with the departments of dermatology, laboratory medicine, and urology. It has already proven successful in solving clinical cases, improving patient's lives.

INiTS
Vienna's High-Tech Incubator

MEDIZINISCHE UNIVERSITÄT WIEN